5VB.F Vaccibody AS
- Market cap
- EUR 92.4M
- P/E
- -
- P/B
- 1.32x
- ROE
- -28.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 5VB.F undervalued?
Graham numberThe Graham number of Vaccibody AS cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Vaccibody AS fundamental analysis
No fundamental analysis for Vaccibody AS yet.
Vaccibody AS stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Vaccibody AS
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include ABI-SUVA for targeting HPV16+ induced malignancies, with head, and neck cancer as the primary indication is in Phase 2 randomized controlled trial. It also offers VB10.NEO, which is in…
Full company profileVaccibody AS financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Vaccibody AS annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 14.8K | 55.5K | 215M | 34.0M | 7.17M | 12.9M | 8.68M | 0.00 | 0.00 |
| Operating Income | -7.56M | -16.1M | 178M | -10.8M | -53.2M | -58.1M | -48.3M | -28.6M | -26.6M |
| EBITDA | -7.31M | -10.8M | 181M | -10.3M | -48.9M | -41.7M | -43.1M | -15.5M | -20.2M |
| Net Income | -7.32M | -14.9M | 150M | -9.41M | -42.7M | -35.2M | -38.8M | -12.2M | -22.6M |
| EPS | -0.03 | -0.05 | 0.53 | -0.03 | -0.15 | -0.11 | -0.12 | -0.04 | -0.07 |
| Balance Sheet | |||||||||
| Total Assets | 18.0M | 33.1M | 230M | 266M | 221M | 208M | 153M | 100.0M | 86.1M |
| Total Liabilities | 2.84M | 2.70M | 51.2M | 71.5M | 64.5M | 36.9M | 17.3M | 8.42M | 5.73M |
| Shareholders' Equity | 15.1M | 30.4M | 179M | 194M | 157M | 171M | 136M | 91.5M | 80.4M |
| Cash & Short-term Investments | 3.63M | 9.87M | 183M | 216M | 206M | 162M | 115M | 59.9M | 44.8M |
| Cash Flow | |||||||||
| Operating Cash Flow | -7.21M | -10.0M | 180M | 1.16M | -20.7M | -96.6M | -51.2M | -29.5M | -31.9M |
| Capital Expenditure | 9.07K | 75.6K | 99.0K | 871K | 2.68M | 1.90M | 71.0K | 38.0K | 0.00 |
| Free Cash Flow | -7.22M | -10.1M | 180M | 284K | -23.4M | -98.5M | -51.3M | -29.5M | -31.9M |
| Ratios | |||||||||
| ROE | -48.4% | -49.1% | 83.7% | -4.9% | -27.2% | -20.5% | -28.5% | -13.4% | -28.1% |
| ROA | -40.8% | -45.1% | 65.1% | -3.5% | -19.3% | -16.9% | -25.3% | -12.2% | -26.2% |
| Net Profit Margin | -49,517.9% | -26,911.1% | 69.7% | -27.7% | -596.3% | -272.5% | -447.3% | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Vaccibody AS dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- May 27, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 32.3M | 0.10 | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Vaccibody AS
- Insiders 36.44%
- Institutions 19.06%
- Public & others 44.50%
- Shares outstanding 392M
- Free float 233M
Vaccibody AS company profile
- Company name
- Vaccibody AS
- Ticker
- 5VB.F
- ISIN
- NO0010714785
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 59
- Fiscal year end
- December
- Address
- Oslo Science Park, Oslo, Norway, 0349
- Phone
- 47 22 95 81 93
- Website
- nykode.com
About Vaccibody AS
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include ABI-SUVA for targeting HPV16+ induced malignancies, with head, and neck cancer as the primary indication is in Phase 2 randomized controlled trial. It also offers VB10.NEO, which is in Phase1b VB-N-02 trial; technology platform, which combines genes with desired properties to make novel compounds by creating a new code. Nykode Therapeutics AS was founded in 2006 and is headquartered in Oslo, Norway.
Vaccibody AS management
5- Mr. Michael Thyring EngsigChief Executive Officer · born 1972
- Dr. Agnete B. Fredriksen Ph.D.Co-Founder & Chief Scientific Officer · born 1978
- Mr. Harald GurvinChief Financial Officer · born 1975
- Mr. Jakob Helding RasmussenChief Technology Officer
- Ms. Louise StubbeChief Legal Officer